INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
FRA:IUI1 - Deutsche Boerse Ag - US46120E6023 - Common Stock - Currency: EUR
Taking everything into account, IUI1 scores 6 out of 10 in our fundamental rating. IUI1 was compared to 57 industry peers in the Health Care Equipment & Supplies industry. IUI1 gets an excellent profitability rating and is at the same time showing great financial health properties. IUI1 is valued quite expensive, but it does show an excellent growth. These ratings could make IUI1 a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
IUI1 had positive earnings in the past year.
IUI1 had a positive operating cash flow in the past year.
IUI1 had positive earnings in each of the past 5 years.
Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 12.93%, IUI1 belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
IUI1 has a Return On Equity of 14.52%. This is amongst the best in the industry. IUI1 outperforms 80.70% of its industry peers.
IUI1 has a better Return On Invested Capital (10.38%) than 84.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 8.20%.
The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(10.38%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.52% | ||
| ROIC | 10.38% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
Looking at the Profit Margin, with a value of 28.51%, IUI1 belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
In the last couple of years the Profit Margin of IUI1 has declined.
IUI1's Operating Margin of 28.93% is amongst the best of the industry. IUI1 outperforms 98.25% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
Looking at the Gross Margin, with a value of 66.61%, IUI1 is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.93% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
IUI1 has more shares outstanding than it did 1 year ago.
IUI1 has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.17
WACC8.87%
2.3 Liquidity
A Current Ratio of 5.64 indicates that IUI1 has no problem at all paying its short term obligations.
IUI1 has a better Current ratio (5.64) than 96.49% of its industry peers.
A Quick Ratio of 4.89 indicates that IUI1 has no problem at all paying its short term obligations.
The Quick ratio of IUI1 (4.89) is better than 98.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.64 | ||
| Quick Ratio | 4.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.97% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.77%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
3.2 Future
The Earnings Per Share is expected to grow by 14.45% on average over the next years. This is quite good.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue Next Year19.56%
Revenue Next 2Y16.91%
Revenue Next 3Y16.15%
Revenue Next 5Y14.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 59.18 indicates a quite expensive valuation of IUI1.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 is on the same level as its industry peers.
When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (26.82), we can say IUI1 is valued expensively.
A Price/Forward Earnings ratio of 51.65 indicates a quite expensive valuation of IUI1.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 63.16% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.21. IUI1 is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.18 | ||
| Fwd PE | 51.65 |
4.2 Price Multiples
64.91% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
IUI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.64 | ||
| EV/EBITDA | 50.07 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IUI1 may justify a higher PE ratio.
IUI1's earnings are expected to grow with 13.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.5
PEG (5Y)5.15
EPS Next 2Y12.18%
EPS Next 3Y13.89%
5. Dividend
5.1 Amount
No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IUI1 (8/1/2025, 7:00:00 PM)
417.8
-8.75 (-2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.74%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap149.77B
Analysts78.97
Price Target517.59 (23.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)-0.28%
PT rev (3m)-0.67%
EPS NQ rev (1m)1.99%
EPS NQ rev (3m)-2.78%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)-2.65%
Revenue NQ rev (1m)0.74%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)1.26%
Revenue NY rev (3m)1.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.18 | ||
| Fwd PE | 51.65 | ||
| P/S | 18.68 | ||
| P/FCF | 85.64 | ||
| P/OCF | 60.44 | ||
| P/B | 9.51 | ||
| P/tB | 9.7 | ||
| EV/EBITDA | 50.07 |
EPS(TTM)7.06
EY1.69%
EPS(NY)8.09
Fwd EY1.94%
FCF(TTM)4.88
FCFY1.17%
OCF(TTM)6.91
OCFY1.65%
SpS22.37
BVpS43.92
TBVpS43.06
PEG (NY)6.5
PEG (5Y)5.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.52% | ||
| ROCE | 14.74% | ||
| ROIC | 10.38% | ||
| ROICexc | 22.12% | ||
| ROICexgc | 23.08% | ||
| OM | 28.93% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% | ||
| FCFM | 21.81% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 144.66% | ||
| Cap/Sales | 9.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.74% | ||
| Profit Quality | 76.48% | ||
| Current Ratio | 5.64 | ||
| Quick Ratio | 4.89 | ||
| Altman-Z | N/A |
F-Score6
WACC8.87%
ROIC/WACC1.17
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.56%
Revenue Next 2Y16.91%
Revenue Next 3Y16.15%
Revenue Next 5Y14.12%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year33.95%
EBIT Next 3Y22.85%
EBIT Next 5Y19.86%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%